An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan

Headache

Volumn 53, Issue 1, 2013, Pages 118-125

  Landy, Stephen H ^a   Tepper, Stewart J ^b   Wein, Theodore ^c   Schweizer, Edward ^d   Ramos, Elodie ^e  

^a Wesley Neurology Clinic   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d Paladin Consulting Group   (United States)

^e PFIZER INC   (United States)

Author keywords

auto injector; headache disorder; migraine headache; sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SINGLE DRUG DOSE;

ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SUMATRIPTAN; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84872099122     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02295.x     Document Type: Article

References (12)

1. Oldman AD, Smith LA, McQuay HJ, Moore RA,. Pharmacological treatments for acute migraine: Quantitative systematic review. Pain. 2002; 97: 247-257.
2. Silberstein SD,. Migraine. Lancet. 2004; 363: 381-391.
3. Tfelt-Hansen P, De Vries P, Saxena PR,. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-1287.
4. Volans GN,. Absorption of effervescent aspirin during migraine. Br Med J. 1974; 2: 265-269.
5. Ferrari A, Tiraferri I, Neri L, Sternieri E,. Why pharmacokinetic differences among oral triptans have little clinical importance: A comment. J Headache Pain. 2011; 12: 5-12.
6. Dodick DW,. Triptan nonresponder studies: Implications for clinical practice. Headache. 2005; 45: 156-162.
7. Lipton RB, Stewart WF,. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache. 1999; 39 (Suppl. 2): S20-S26.
8. Lipton RB, Cutrer FM, Goadsby PJ, et al. How treatment priorities influence triptan preferences in clinical practice: Perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin. 2005; 21: 413-424.
9. Turner AP, Williams RM, Sloan AP, Haselkorn JK,. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol. 2009; 54: 116-121.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1998; 8 (Suppl. 7): 1-96.
11. Newcombe GR,. Two-sided confidence intervals for the single proportion. Statist Med. 1998; 17: 857-872.
12. Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache. 2011; 51: 1202-1211.